These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24188746)

  • 41. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer.
    Kim JS; Kim JS; Cho MJ; Song KS; Yoon WH
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):403-8. PubMed ID: 12243814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial.
    Heudel P; Romestaing P; Barbet N; Falandry C; You B; Glehen O; Freyer G
    Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):369-74. PubMed ID: 18406583
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: a phase II multi-institutional clinical trial (KROG 11-02).
    Lee JH; Kim JG; Oh ST; Lee MA; Chun HG; Kim DY; Kim TH; Kim SY; Baek JY; Park JW; Oh JH; Park HC; Choi DH; Park YS; Kim HC; Chie EK; Jang HS
    Radiother Oncol; 2014 Jan; 110(1):150-4. PubMed ID: 24411228
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Feasibility study on Xelox (capecitabine plus oxapliplatin) in the volumetric modulated arc therapy (VMAT)-based preoperative chemoradiotherapy for locally advanced rectal cancer].
    Xiao L; Huang R; You K; Chang H; Qiu B; Xiao W; Chen L; Gao Y; Liu M
    Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Mar; 17(3):219-24. PubMed ID: 24671807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pilot study of intense neoadjuvant chemoradiotherapy for locally advanced rectal cancer: retrospective review of a phase II study.
    Xu BH; Chi P; Guo JH; Guan GX; Tang TL; Yang YH; Chen MQ; Song JY; Feng CY
    Tumori; 2014; 100(2):149-57. PubMed ID: 24852858
    [TBL] [Abstract][Full Text] [Related]  

  • 46. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
    Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparing pathological complete response rate using oral capecitabine versus infusional 5-fluorouracil with preoperative radiotherapy in rectal cancer treatment.
    Jootun N; Evans T; Mak J; Makin G; Platell C
    ANZ J Surg; 2018 Jan; 88(1-2):62-65. PubMed ID: 28982208
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response.
    Klautke G; Küchenmeister U; Foitzik T; Ludwig K; Semrau S; Prall F; Klar E; Fietkau R
    Radiother Oncol; 2007 Dec; 85(3):379-84. PubMed ID: 18036687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study.
    Kamiya T; Uehara K; Nakayama G; Ishigure K; Kobayashi S; Hiramatsu K; Nakayama H; Yamashita K; Sakamoto E; Tojima Y; Kawai S; Kodera Y; Nagino M;
    Eur J Surg Oncol; 2016 Jun; 42(6):829-35. PubMed ID: 26968228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
    J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204.
    Landry JC; Feng Y; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Prabhu RS; Benson AB
    Cancer; 2013 Apr; 119(8):1521-7. PubMed ID: 23288663
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
    Moureau-Zabotto L; Farnault B; de Chaisemartin C; Esterni B; Lelong B; Viret F; Giovannini M; Monges G; Delpero JR; Bories E; Turrini O; Viens P; Salem N
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):483-91. PubMed ID: 21093174
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
    Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A
    Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis.
    Das P; Lin EH; Bhatia S; Skibber JM; Rodriguez-Bigas MA; Feig BW; Chang GJ; Hoff PM; Eng C; Wolff RA; Delclos ME; Krishnan S; Janjan NA; Crane CH
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1378-83. PubMed ID: 17056196
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes of Preoperative Chemoradiotherapy and Combined Chemotherapy with Radiotherapy Without Surgery for Locally Advanced Rectal Cancer.
    Supaadirek C; Pesee M; Thamronganantasakul K; Thalangsri P; Krusun S; Supakalin N
    Asian Pac J Cancer Prev; 2016; 17(7):3511-4. PubMed ID: 27510001
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
    Swellengrebel HA; Bosch SL; Cats A; Vincent AD; Dewit LG; Verwaal VJ; Nagtegaal ID; Marijnen CA
    Radiother Oncol; 2014 Jul; 112(1):44-51. PubMed ID: 25018000
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
    Glynne-Jones R; Falk S; Maughan TS; Meadows HM; Sebag-Montefiore D
    Br J Cancer; 2007 Feb; 96(4):551-8. PubMed ID: 17262086
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.
    Machiels JP; Duck L; Honhon B; Coster B; Coche JC; Scalliet P; Humblet Y; Aydin S; Kerger J; Remouchamps V; Canon JL; Van Maele P; Gilbeau L; Laurent S; Kirkove C; Octave-Prignot M; Baurain JF; Kartheuser A; Sempoux C
    Ann Oncol; 2005 Dec; 16(12):1898-905. PubMed ID: 16219623
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
    Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
    Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preoperative long-course chemoradiation for localized rectal cancer: A retrospective comparison of response and outcome between 5-fluorouracil/leucovorin versus capecitabine.
    Kunheri B; Gurram B; Madhavan R; Makuny D
    Indian J Cancer; 2016; 53(4):518-523. PubMed ID: 28485342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.